Evaluation of three molecular methods for tracking and identifying HER2/neu oncogene in breast cancer patients
Article Sidebar
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Downloads
Societal impact
Main Article Content
Abstract
Objective: to compare IHC, FISH and quantitative real-time PCR techniques, in the determination of HER2/neu oncogene amplification and overexpression in 70 breast cancer patients.
Methods: we evaluated the performance of the IHC HercepTest and quantitative real-time PCR techniques, using as a gold standard the fluorescent in situ hybridization technique. We determined the positivity percentage of the breast neoplasms that have the amplification for HER2/neu oncogene.
Results: 38% of breast tumors demonstrate amplification of HER2/neu oncogene according to real-time PCR and we found an 80% concordance for real-time PCR and FISH in cases classified as equivocal or grade 2+ with IHC.
Conclusion: the results of this study suggest that the analysis by real-time PCR is a valid alternative in cases when it is not possible to use the FISH technique for reassessment of breast neoplasms classified as equivocal or grade 2+ for HER2/neu with IHC. The combination of IHC and quantitative real-time PCR may be a good approach in the determination of the expression and amplification status of HER2/neu in breast cancer patients.
Article Details
References
Tavassoli FA, Devilee P, editors. World Health Organization; classification of tumors: tumors of the breast and female genital organs. Invasive breast carcinoma. Geneva: WHO; 2003. p13.
Pitch A, Margaria E, Chiusa L. Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival. J Clin Oncol. 2000;18(16):2948-2956.
Dickson RB, Jhonson MD, Bano M, Shi E, Kurebayashi I, Ziff B, et al. Growth factors in breast cancer: mitogenesis to transformation. J Steroid Biochenrn Mol Biol. 1992; 43(1-3):69-78.
DANE. Sistema de registro civil y estadísticas vitales: certificados de nacido vivo y defunción. Bogotá: DANE; 2004.
Piñeros M, Murillo R. Incidencia del cáncer en Colombia: importancia de las fuentes de información en la obtención de cifras estimativas. Rev. Colomb. Cancerol. 2004; 8:5-14.
Hospital Pablo Tobón Uribe. Departamento de Gestión de Información Clínica. Medellín: HPTU; 2006.
Vogel GV. Breast cancer prevention: a review of current evidence.CA Cancer J Clin. 2000; 50(3):156-170.
Yamashita H, Nishio N, Toyama T, Sugiura H, Zhang Z, Kobayashi S, et al. Coexistence of HER2 overexpression and p53 protein accumulation is a strong prognostic molecular marker in breast Cancer. Breast Cancer Res. 2004; 6 (1):24-30.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
Gjerdrum LM, Sorensen BS, Kjeldensen E, Sorensen FB, Nexo E, Hamilton-Dutoit S. Real time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for Her-2/neu analysis. J Mol Diagn. 2004; 6 (1):42-51.
Madrid MA, Lo RW. Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu. Breast Cancer Res. 2004; 6: R593-R600.
Nistor A, Watson PH, Pettigrew N, Tabiti K, Dawson A, Myal Y. Real time PCR complements inmunohistochemestry in the determination of HER-2/neu status in breast cancer. BMC Clin Pathol. 2006; 6 (2):1-8.
Cullen KJ, Smith HS, Hill S, Rosen N, Lippman ME. Growth factor messenger RNA expression by human breast fibroblast from bening and malignant lesions. Cancer Res. 1991;51:4978-4985.
NCI. National Cancer Institute [sede web]. Bethesda, MD: NCI; 2004 [fecha de acceso 25 de mayo de 2006]. Disponible en: http://www.cancer.gov.
Medline Plus. Cáncer de mama [Internet]. Bethesda, MD: National Library Medicine; 2007 [fecha de acceso 6 de abril de 2007]. Disponible en: http://www.nlm.nih.gov/ medlineplus/spanish/ency/article/000913.htm#top
Dirección Seccional de Salud Antioquia. Registro poblacional de cáncer de Antioquia. Medellín: DSSA; 2005.
Asociación Española Contra el Cáncer. Información del Congreso Americano de Oncología Médica (ASCO), celebrado en junio de 2006. Madrid: AECC; 2006 [fecha de acceso 3 de junio de 2007]. Disponible en: http:// www.muchoxvivir.org/index.jsp?seccion=394.
Hoang MP, Sahin AA, Ordòñez NG, Sneige N. HER-2/ neu gene amplification compared with her-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Pathol. 2000; 113 (6); 855-859.
Ménard S, Balsari A, Casalini P, Tagliabue E, Campiglio M, Bufalino R, et al. HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clin Cancer Res. 2002; 8: 520-525.
Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiol Rev. 1993;15: 48–65.
Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev. 1993; 15:17–35.
Britton JA, Gammon MD, Schoenberg JB, Stanford JL, Coates RJ, Swanson CA, et al. Risk of breast cancer classified by joint estrogen receptor and progesterone receptor status among women 20–44 years of age. Am J Epidemiol.2002; 156: 507–16.
Jaramillo C, Bravo LE, Carrascal E, Tamayo O. Expresión de receptores hormonales frente a indicadores pronósticos en carcinoma de mama. Colombia Médica. 2002; 33:156-161.
Rhodes A, Borthwick D, Sykes R, Al-Sam S, Paradiso A. The use of cell line standards to reduce HER-2/neu assay variation in multiple european cancer centers and the potential of automated image analysis to provide for more accurate cut points for predicting clinical response to Trastuzumab. Am J Clin Pathol. 2004; 122 (1):51-60.
Forbes JF. The control of breast cancer: the role of tamoxifen. Semin Oncol. 1997;24 (suppl 1):S1-5-S1- 19.
Pinder SE, Ellis IO. The diagnosis and magnament of pre-invasive breast disease: ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH) – current definitions and classification. Breast cancer Res. 2003; 5: 254-257.
Crabtree B, Neme Y, Rivera S, Olivares G. Hormone receptors, HER2/neu and p53 in 1027 Mexican patients with breast cancer. J Clin Oncol. 2005; 23(16S):903.
Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L, et al. Elevated serum HER-2/neu levels predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol. 2002;20(6):1467.
Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW. Over-expression of c-erb2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer. 1999; 79: 1220-26.
Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Säve-Söderborgh J, Anbazhagan R, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 1992;10(7):1049-56.
Lal P, Tan LK, Chen B. Correlation of HER-2 Status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinoma. Am J Clin Pathol.2005; 123 (4): 541-546.
Dybdal N, Leirberman G, Anderson S, Mccune B, Bajamonde A, Cohen RL, et al. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat. 2005; 93(1):3-11.
Wang S, Hossein Saboorian S, Frenkel EP, Haley BB, Siddiqui MT, Gokaslan S, et al. Assessment of HER-2/neu status in breast cancer: automated cellular imaging system (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol.2001; 116:495- 503.
Bernard PS, Wittwer CT. Real time technology for cancer diagnostics. Clin Chem.2002; 48(8):1178-1185.
Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol. 1999;17: 1974-1982
Tsuda H, Akiyama F, Terasaki H, Hasegawa T, Kurosumi M, Shimadzu M, et al. Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma: inter-observer reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer. 2001; 92: 2965-2974.
Milson A, Suli A, Hartung L, Kunitake S, Bennett A, Noderberg L, et al. Comparison of two quantitative polymerase chain reaction methods for detecting HER-2/neu. J Mol Diagn. 2003; 5(3):184-190.
Tse C, Brault D, Gligorov J, Antoine M, Neumann R, Lotz JP, et al. Evaluation of the quantitave analytical methods real-time PCR for HER-2 gene quantification and ELISA of serum HER-2 protein and comparison with fluorescence in situ hybridization and immunohistochemistry for determining HER-2 status in breast cancer patients. Clin Chem. 2005;51(7):1093- 1101
Molinero LM. Errores de medida en variables numéricas: correlación y concordancia. Madrid: Asociación de la Sociedad Española de Hipertensión; 2001 [fecha de acceso 3 de Junio de 2007]. Disponible en: http://www. seh-lelha.org/concor1.htm
Calmaestra LB. Correlación lineal: distribuciones bidimensionales. Madrid: Ministerio de Educación; 2005 [fecha de acceso 3 de junio de 2007]. Disponible en: http://descartes.cnice.mecd. es/Estadistica/ bidimensional_ lbarrios/ecorrelacion_est.htm
Järvinen TA, Tanner M, Rantanen V, Bärlund M, Borg A, Grénman S, et al. Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol. 2000; 156( 3):839-847.
Schlemmer BO, Sorensen BS, Overgaard J, Olsen KE, Gjerdrum LM, Nexo E. Quantitative PCR a new diagnosticto for quantifying specific mRNA and DNA molecules:Her2/neu DNA quantification with LightCycler real-timePCR in comparison with immunohistochemistry andfluorescence in situ hybridization. Scand J Clin Lab Invest. 2004; 64: 511-522.
Dillon D. Molecular markers in the diagnosis and staging of breast cancer. Semin Radiat Oncol. 2002;12:305-318.
Bruse SM, Waldelmann E, Behrens P, Losen I, Buettner R, Friedrichs N. Current Diagnostic Methods of HER-2/ neu Detection in Breast Cancer With Special Regard to real-time PCR. Am J Surg Pathol. 2003;27(12).
Hoque A, Sneige N, Sahin AA, Menter DG, Bacus JW, Hortobagyi GN, et al. HER-2/neu gene amplification in ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev. 2002;11:587-590.
Latta EK, Tjan S, Parkes RK, O´Malley MB. The role of HER2/neu overexpression/amplificaction in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol. 2002;15(12):1318- 1325.
Burstein HJ, Polyak K, Wong JS Lester S, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med. 2004;350:1340-1341
Hannemann J, Velds A, Halfwek JBG, Kreike B, Peterse JL, Van de Vijver M. Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res. 2006;8:R61.
Park K, Kim HJ, Kim J, Shim E. HER2 status in pure ductal carcinoma in situ and the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopatology. 2006; 48:702- 707.
Dowsett M, Bartlett J, Ellis IO, Salter J, Hills M, Mallon E, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol. 2003;199(4):418-423.
Arnould L, Denoux Y, MacGrogan GM, Penault-Llorca F, Fiche M, Treilleux I, et al. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer. 2003; 88:1587-1591.
Fleiss JL. Statistical methods for rates and proportions. 2. ed. New York:Wiley; 2000
Ochoa SC, González DJ, Hernandez M, Buñel AJC. Evaluación de artículos científicos sobre pruebas diagnósticas. Evid Pediatr. 2007; 3: 24.
Molinero LM. Valoración de pruebas diagnósticas. Madrid: Asociación de la Sociedad Española de Hipertensión; 2002 [fecha de acceso 3 de Junio de 2007]. Disponible en: http://www.seh-lelha.org/concor1.htm
Altman DG, Bland JM. Statistics notes: diagnostic tests 3: receiver operating characteristic plots. BMJ. 1994; 309:188.
López de Ullibarri GI, Pita FS. Metodología de la investigación. Medidas de concordancia: el índice Kappa. Cad Aten Primaria.1999; 6:169-171.
Altman DG, Bland MJ. Statics notes: diagnostic test 2: predictive values. BMJ.1994; 309:102.
Sierra F. La sensibilidad y especificidad: entendiendo su origen y utilidad real. Rev Colomb Gastroenterol. 2003;18:180-182.
Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Amplification of DNA using the PCR technique. In: Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular Biology of the Cell. 4. ed. New York: Garland Science; 2002. p. 1426-1429.
Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, et al. Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer. Ann Oncol. 2005;16(11):1755-1761.
Thomson TA, Hayes MM, Spinelli JJ, Hilland E, Sawrenko C, Phillips D, et al. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol. 2001;14:1079-1086.
McCormick SR, Lillemoe TJ, Beneke J, Schrauth J, Reinartz J. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. Am J Clin Pathol. 2002;117: 935-943.
Zarbo RJ, Hammond MEH. Conference Summary, Strategic Science Symposium. Her-2/neu testing of breast cancer patients in clinical practice. Arch Pathol Lab Med. 2003; 127: 549-553.